GW Pharmaceuticals PLC (NASDAQ:GWPH) received a $135.00 target price from research analysts at Maxim Group in a report issued on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 14.79% from the company’s previous close.

GWPH has been the subject of several other research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $208.00 price target on shares of GW Pharmaceuticals PLC in a report on Tuesday, May 9th. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Monday, July 24th. TheStreet lowered shares of GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a report on Wednesday, May 10th. BidaskClub raised shares of GW Pharmaceuticals PLC from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 14th. Finally, ValuEngine raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $156.38.

Shares of GW Pharmaceuticals PLC (NASDAQ GWPH) traded down 1.80% on Monday, hitting $115.49. 551,068 shares of the stock traded hands. The stock’s market cap is $2.92 billion. GW Pharmaceuticals PLC has a 52-week low of $79.62 and a 52-week high of $137.88. The stock’s 50 day moving average price is $105.72 and its 200 day moving average price is $113.95.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.50) by $0.20. The company had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $2.07 million. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. GW Pharmaceuticals PLC’s revenue was down 23.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.06) EPS. On average, equities analysts expect that GW Pharmaceuticals PLC will post ($5.10) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “GW Pharmaceuticals PLC (GWPH) Given a $135.00 Price Target by Maxim Group Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/07/gw-pharmaceuticals-plc-gwph-given-a-135-00-price-target-by-maxim-group-analysts.html.

Several large investors have recently added to or reduced their stakes in GWPH. Jennison Associates LLC raised its stake in GW Pharmaceuticals PLC by 212.1% in the first quarter. Jennison Associates LLC now owns 466,345 shares of the biopharmaceutical company’s stock worth $56,400,000 after buying an additional 316,926 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth about $10,909,000. Nomura Holdings Inc. acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth about $9,389,000. Pictet Asset Management Ltd. raised its stake in GW Pharmaceuticals PLC by 81.1% in the first quarter. Pictet Asset Management Ltd. now owns 128,571 shares of the biopharmaceutical company’s stock worth $15,549,000 after buying an additional 57,578 shares during the last quarter. Finally, Clough Capital Partners L P raised its stake in GW Pharmaceuticals PLC by 107.6% in the first quarter. Clough Capital Partners L P now owns 98,200 shares of the biopharmaceutical company’s stock worth $11,876,000 after buying an additional 50,900 shares during the last quarter. 75.77% of the stock is owned by institutional investors and hedge funds.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.